Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2012 by British Columbia Cancer Agency.
Recruitment status was:  Not yet recruiting
Sponsor:
Collaborator:
Ferring Pharmaceuticals
Information provided by (Responsible Party):
Kim Chi, British Columbia Cancer Agency
ClinicalTrials.gov Identifier:
NCT01630967
First received: June 25, 2012
Last updated: June 27, 2012
Last verified: June 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: December 2013
  Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Publications: